Skip to main content

Patricia Pozo Rosich

I am a doctor of medicine, specialist in neurology. I am head of the Neurology Service of Vall d'Hebron. I lead the Research Laboratory in Cephalea and Neurological Pain of the VHIR (Vall d’Hebron Research Institute) belonging to the Autonomous University of Barcelona (UAB).

Institutions of which they are part

Head of group
Headache and Neurological Pain
Vall Hebron Institut de Recerca
Neurology
General Hospital
Patricia Pozo Rosich

Patricia Pozo Rosich

Patricia Pozo Rosich

Institutions of which they are part

Head of group
Headache and Neurological Pain
Vall Hebron Institut de Recerca
Neurology
General Hospital

I am a doctor of medicine, specialist in neurology. I am head of the Neurology Service of Vall d'Hebron. I lead the Research Laboratory in Cephalea and Neurological Pain of the VHIR (Vall d’Hebron Research Institute) belonging to the Autonomous University of Barcelona (UAB).

I am a member of the Executive Committee of the International Headache Society and the European Headache Federation and of the Committee for Clinical Trials of the International Headache Society. In addition, I am a member of the American Headache Society.

I specialized in the field of headache in the United States and London, in the laboratories of Professor Silberstein (Thomas Jefferson University) and Professor Goadsby (University of California at San Francisco and University College London – Queen Square), with the help of the “la Caixa” scholarships, AHS, EFNS, Rio Hortega, GECSEN.

My interest in the field of research focuses on better understanding the pathophysiology of migraine from a multidisciplinary approach using genetics, neuroimaging and electrophysiology. I have developed the Migraine Adaptive Brain research program that focuses on the neurosensory brain. I am a member of the International Consortium of Migration Genetics.

To carry out research projects I have received grants from the “la Caixa” Banking Foundation, the FIS (Health Research Fund) of the Carlos III Institute, the La MaratóTV3 Foundation, Migraine Research Foundation, MICINN (Ministry of Science and Innovation) and the Mutual Medical.

I am editor of the journals Frontiers in Neurology, Journal of Headache and Pain and director of the Cephalia Area of the Neurology Journal. I have published original articles in impact factor journals, review articles, book chapters, edited books and magazines and I am the author of books.

I also work in education. I am a clinical associate professor at the Autonomous University of Barcelona.

Projects

Biomarcadores neuroinflamatorios en pacientes con migraña: prueba de concepto para el diagnóstico molecular de la enfermedad

IP: Marta Vila Pueyo
Collaborators: Laila Asskour, Patricia Pozo Rosich, Victor José Gallardo Lopez, Otilia Gliga
Funding agency: Fundación Eugenio Rodríguez Pascual
Funding: 24990
Reference: FERP-2023-MVP
Duration: 17/01/2024 - 16/01/2026

Digitalization in Migraine

IP: Patricia Pozo Rosich
Collaborators: Edoardo Caronna, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 180000
Reference: JR23/00065
Duration: 01/01/2024 - 31/12/2027

X

IP: Patricia Pozo Rosich
Collaborators: Otilia Gliga, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 89900
Reference: FI23/00149
Duration: 01/01/2024 - 31/12/2027

(PREDIMIGRAINE) Medicina de precisión para prevenir la cronificación de la migraña a través de la predicción de las crisis de dolor y de la respuesta al tratamiento con anticuerpos anti-CGRP utilizando estrategias multi-ómicas.

IP: Patricia Pozo Rosich
Collaborators: Alicia Alpuente Ruiz, Laila Asskour, Eulalia Gine Cipres, Victor José Gallardo Lopez, Edoardo Caronna
Funding agency: Instituto de Salud Carlos III
Funding: 369930
Reference: PMP22/00189
Duration: 01/01/2023 - 31/12/2025

Related news

Two international studies led by Vall d'Hebron recommend early administration of specific drugs to prevent migraine to achieve a better response to therapy.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

The study, conducted in more than 770 people, concludes that atogepant reduces the frequency of migraine attacks and the need to take medication.

Related professionals

Montse  Adell  Trape

Montse Adell Trape

General Surgery
Read more
Laia Josa Culleré

Laia Josa Culleré

Postdoctoral researcher
Head and Neck Cancer: Biomedical Research Cancer Stem cells
Read more
Maria Garcia Carrasco

Maria Garcia Carrasco

Reconstructive Surgery of the Locomotor System
Read more
Ester Sanchez Gavilan

Ester Sanchez Gavilan

Research technician
Stroke research
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.